AstraZeneca: Consistent Growth And Upcoming Catalysts Make This A Buy (NASDAQ:AZN)

AstraZeneca is a leading global pharmaceutical company with strong growth in oncology, diversified revenues, and a robust pipeline. Click to read why AZN is a Buy.